Radiation oncology clinical trials - Peter MacCallum Cancer Centre

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information.

For more information on radiation oncology clinical trials, get in contact with our team at This email address is being protected from spambots. You need JavaScript enabled to view it..

Open and Recruiting Clinical Trials

EXPERT

A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer

Trial ID

NCT02889874

Cancer type

Low-risk early breast cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

As a standard treatment, patients with low risk breast cancer have surgery to remove the tumour followed by radiotherapy and hormonal treatment to improve the chances of cancer not returning. Doctors do not know whether it is safe to omit radiotherapy treatment in these patients to prevent over treating them. The trial aims to improve personalised use of radiation therapy in early breast cancer patients, according to their individual risk of the cancer reoccurring. The results from EXPERT trial will help doctors decide the most effective and safest approach and what treatment to recommend in the future.

Patients participating in this trial will be randomly allocated to one of two treatment groups:

Group A: Radiotherapy and endocrine therapy
Group B: Endocrine therapy only

Who can participate

Women aged 50 years or older who have undergone surgery to remove hormone receptor positive early breast cancer and is prescribed to receive radiotherapy and hormonal therapy as part of standard treatment.

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Victorian Cancer Trials Link.

STABLE-MATES

A randomised Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

Trial ID

NCT02468024

Cancer type

Non-small cell Lung Cancer (NSCLC)

Status

Open and recruiting

Phase

Brief summary

This trial is being done to compare the results of two standard treatments for early stage NSCLC:

Treatment A: sublobar resection (removal of a small portion of a lung)
Treatment B: SABR (Stereotactic Ablative Radiotherapy)

The aim of this study is to determine if radiotherapy treatment (SAbR) improves patient survival over having a sublobar resection (SR) in high risk, operable, Stage I NSCLC.

Who can participate

Adults who have operable Stage 1 Non-Small Cell Lung Cancer (NSCLC) who are considered ‘high risk’ as determined by their doctor because of the condition of their heart and lungs.

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

For full inclusion / exclusion criteria refer to the Victorian Cancer Trials Link.

Local HER-O

A Phase II study of local therapy only (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive Breast Cancer

Cancer type

Metastatic breast

Status

Open and recruiting

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

This study is looking at how well tumours in the brain are controlled by stereotactic radiosurgery (SRS) and or neurosurgery (NS). The treatment offered will be determined by the patient’s doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases. Each treatment will be performed by the specialist in that field, i.e. neurosurgeon and/or radiation oncologist.

Who can participate

Women who have Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancer, which has metastasised to the brain.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.